Results 51 to 60 of about 35,072 (188)

Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis

Frontiers in Immunology, 2021
Adalimumab, as a TNF inhibitor biologic for the treatment of rheumatoid arthritis, is one of the top-selling drugs worldwide. As its various patents have gradually expired, experiments on its biosimilars are constantly being implemented.
Xiaoqin Lu, Rui Hu, Lin Peng, Mengsi Liu, Zhen Sun   +4 more
semanticscholar   +1 more source

HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.

Gastroenterology, 2019
BACKGROUND & AIMS Anti-tumor necrosis factor (anti-TNF) therapies are the most widely used biologic drugs for treating immune-mediated diseases, but repeated administration can induce the formation of anti-drug antibodies.
Aleksejs Sazonovs, N. Kennedy, L. Moutsianas, G. Heap, D. Rice, M. Reppell, C. Bewshea, N. Chanchlani, G. Walker, M. Perry, T. Mcdonald, C. Lees, J. Cummings, M. Parkes, J. Mansfield, P. Irving, J. Barrett, D. McGovern, J. Goodhand, C. Anderson, Tariq Ahmad, V. Patel, Zia Mazhar, R. Saich, B. Colleypriest, T. Tham, T. Iqbal, V. Kaushik, S. Murugesan, Salil Singh, S. Weaver, C. Preston, Assad M. Butt, Melissa A. Smith, D. Basude, A. Beale, S. Langlands, N. Direkze, F. Torrente, Juan De La Revella Negro, Chris Ewen MacDonald, S. Evans, A. Gunasekera, Alka Thakur, D. Elphick, Achuth H. Shenoy, C. Nwokolo, A. Dhar, A. Cole, A. Agrawal, S. Bridger, J. Doherty, S. Cooper, S. de Silva, C. Mowat, P. Mayhead, C. Lees, Gareth T. Jones, J. W. Hart, D. Gaya, R. Russell, L. Gervais, P. Dunckley, T. Mahmood, P. Banim, S. Sonwalkar, Deb Ghosh, R. H. Phillips, A. Azaz, S. Sebastian, R. Shenderey, L. Armstrong, Claire Bell, R. Hariraj, Helen Matthews, H. Jafferbhoy, C. Selinger, V. Zamvar, J. de Caestecker, Anne Willmott, Richard Miller, Palani Sathish Babu, C. Tzivinikos, S. Bloom, G. Chung-Faye, N. Croft, J. Fell, M. Harbord, A. Hart, B. Hope, P. Irving, J. Lindsay, J. Mawdsley, A. Mcnair, K. Monahan, C. Murray, T. Orchard, Thankam Paul, R. Pollok, Neil Shah, S. Bouri, Matt W. Johnson, Anita Modi, Kasamu Dawa Kabiru, B. Baburajan, B. Bhaduri, Andrew Adebayo Fagbemi, S. Levison, J. Limdi, G. Watts, S. Foley, A. Ramadas, G. Macfaul, J. Mansfield, L. Grellier, M. Morris, M. Tremelling, C. Hawkey, S. Kirkham, C. Charlton, A. Rodrigues, A. Simmons, Stephen J. Lewis, J. Snook, M. Tighe, P. Goggin, A. De Silva, S. Lal, Mark S. Smith, S. Panter, Fraser Cummings, Suranga Dharmisari, M. Carter, D. Watts, Z. Mahmood, B. Mclain, S. Sen, A. J. Pigott, D. Hobday, E. Wesley, R. Johnston, C. Edwards, J. Beckly, D. Vani, S. Ramakrishnan, R. Chaudhary, N. Trudgill, R. Cooney, A. Bell, Neeraj Prasad, J. Gordon, M. Brookes, Andy Li, S. Gore   +153 more
semanticscholar   +1 more source

Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.

The Lancet Gastroenterology and Hepatology, 2021
BACKGROUND Biologic treatment options are limited for children with ulcerative colitis. The aim of this study was to assess the safety and efficacy of adalimumab in children with moderate-to-severe ulcerative colitis.
N. Croft, W. Faubion, S. Kugathasan, J. Kierkuś, F. Ruemmele, Toshiaki Shimizu, N. Mostafa, M. Venetucci, T. Finney-Hayward, Y. Sanchez Gonzalez, M. Bereswill, A. Lazar, D. Turner   +12 more
semanticscholar   +1 more source

Spatial‐hindrance‐based pro‐Adalimumab prevents anti‐idiotypic antibody interference in pharmacokinetic and therapeutic efficacy

Bioengineering & Translational Medicine
Adalimumab (Humira) represents a major advance in rheumatoid arthritis (RA) therapy. However, with long‐term administration of Adalimumab, anti‐idiotypic antibody (anti‐Id Ab) accelerates the Adalimumab clearance rate and reduces the therapeutic effect ...
Bo‐Cheng Huang, Yu‐Tung Chen, Yun‐Chi Lu, Kai‐Wen Ho, Shih‐Ting Hong, Tzu‐Yi Liao, I‐Hsuan Wu, En‐Shuo Liu, Jun‐Min Liao, Fang‐Ming Chen, Chia‐Ching Li, Chih‐Hung Chuang, Chiao‐Yun Chen, Tian‐Lu Cheng   +13 more
doaj   +1 more source

Switching between reference adalimumab and biosimilars in chronic immune‐mediated inflammatory diseases: A systematic literature review

British Journal of Clinical Pharmacology, 2021
Adalimumab is a biological therapy used to treat different chronic inflammatory diseases. At present, there is an increasing number of adalimumab biosimilars. To assume the acceptability of interchangeability between reference adalimumab and biosimilars,
J. M. Pego Reigosa, N. García Beloso, Irene Altabás González, M. Samartin Ucha, M. Gayoso Rey, M. L. De Castro Parga, Á. Salgado Barreira, Amelia Cibeira Badia, María Guadalupe Piñeiro Corrales, Daniel González Vilas, J. M. Pego Reigosa, Noemí Martínez López de Castro   +11 more
semanticscholar   +1 more source

The efficacy of adalimumab in treating patients with central multifocal choroiditis

American Journal of Ophthalmology Case Reports, 2020
Purpose: To evaluate the efficacy of adalimumab in patients with central multifocal choroiditis (cMFC) refractory to conventional corticosteroid-sparing immunomodulatory agents (IMT). Methods: Medical records were reviewed from all patients with cMFC and
Evianne L. de Groot, Jeannette Ossewaarde - van Norel, Lintje Ho, Ninette H. ten Dam - van Loon, Joke H. de Boer   +4 more
doaj   +1 more source

Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis

JAMA Dermatology
ImportanceIt is unclear whether concomitant methotrexate enhances the effectiveness and persistence of adalimumab for psoriasis. The recent OPTIMAP randomized clinical trial that tested adalimumab against adalimumab with methotrexate could not adequately answer this question due to underrecruitment.ObjectiveTo determine the effectiveness of using ...
Yiu, Zenas Z N, Smith, Catherine H, Laws, Philip, Hampton, Philip J, Griffiths, Christopher E M, Warren, Richard B   +5 more
openaire   +2 more sources

Adalimumab: A key element in the treatment strategy for immune-mediated inflammatory diseases: A review [PDF]

Consilium Medicum
Adalimumab is a biological drug effectively used in the treatment of several immune-mediated inflammatory diseases, including ankylosing spondylitis, juvenile idiopathic arthritis, and psoriasis.
Mariam A. Gilavian, Daria V. Trunova, Anastasia V. Ustinova, Anna M. Sukhanova   +3 more
doaj   +1 more source

Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients

Journal of Crohn's & Colitis, 2021
Background and Aims Infliximab attenuates serological responses to SARS-CoV-2 infection. Whether this is a class effect, or if anti-tumour necrosis factor [anti-TNF] level influences serological responses, remains unknown.
N. Chanchlani, Simeng Lin, D. Chee, B. Hamilton, R. Nice, Arkir Zehra, C. Bewshea, B. Cipriano, L. Derikx, A. Dunlop, L. Greathead, Rachel L Griffiths, H. Ibraheim, P. Kelleher, K. Kok, C. Lees, J. Macdonald, S. Sebastian, Philip Smith, T. Mcdonald, P. Irving, N. Powell, N. Kennedy, J. Goodhand, Tariq Ahmad   +24 more
semanticscholar   +1 more source

Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.

JAMA dermatology, 2021
Importance The efficacy of adalimumab biosimilars is similar to that of brand-name adalimumab (Humira, hereinafter originator) in clinical trials. However, limited knowledge about real-world data exists for adalimumab biosimilars.
N. Loft, A. Egeberg, M. Rasmussen, L. Bryld, C. V. Nissen, T. N. Dam, K. Ajgeiy, L. Iversen, L. Skov   +8 more
semanticscholar   +1 more source